Literature DB >> 9525604

Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

K Wiegers1, G Rutter, H Kottler, U Tessmer, H Hohenberg, H G Kräusslich.   

Abstract

Retroviruses are produced as immature particles containing structural polyproteins, which are subsequently cleaved by the viral proteinase (PR). Extracellular maturation leads to condensation of the spherical core to a capsid shell formed by the capsid (CA) protein, which encases the genomic RNA complexed with nucleocapsid (NC) proteins. CA and NC are separated by a short spacer peptide (spacer peptide 1 [SP1]) on the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein and released by sequential PR-mediated cleavages. To assess the role of individual cleavages in maturation, we constructed point mutations abolishing cleavage at these sites, either alone or in combination. When all three sites between CA and NC were mutated, immature particles containing stable CA-NC were observed, with no apparent effect on other cleavages. Delayed maturation with irregular morphology of the ribonucleoprotein core was observed when cleavage of SP1 from NC was prevented. Blocking the release of SP1 from CA, on the other hand, yielded normal condensation of the ribonucleoprotein core but prevented capsid condensation. A thin, electron-dense layer near the viral membrane was observed in this case, and mutant capsids were significantly less stable against detergent treatment than wild-type HIV-1. We suggest that HIV maturation is a sequential process controlled by the rate of cleavage at individual sites. Initial rapid cleavage at the C terminus of SP1 releases the RNA-binding NC protein and leads to condensation of the ribonucleoprotein core. Subsequently, CA is separated from the membrane by cleavage between the matrix protein and CA, and late release of SP1 from CA is required for capsid condensation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525604      PMCID: PMC109729     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells.

Authors:  K Mergener; M Fäcke; R Welker; V Brinkmann; H R Gelderblom; H G Kräusslich
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

2.  Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation.

Authors:  A von Poblotzki; R Wagner; M Niedrig; G Wanner; H Wolf; S Modrow
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

3.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.

Authors:  S Campbell; V M Vogt
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.

Authors:  W Paxton; R I Connor; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein.

Authors:  R C Craven; A E Leure-duPree; C R Erdie; C B Wilson; J W Wills
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

8.  Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus.

Authors:  J H Elder; M Schnölzer; C S Hasselkus-Light; M Henson; D A Lerner; T R Phillips; P C Wagaman; S B Kent
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.

Authors:  J B Jowett; D J Hockley; M V Nermut; I M Jones
Journal:  J Gen Virol       Date:  1992-12       Impact factor: 3.891

10.  Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.

Authors:  J Park; C D Morrow
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

View more
  189 in total

1.  Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.

Authors:  C Liang; L Rong; Y Quan; M Laughrea; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab.

Authors:  C Berthet-Colominas; S Monaco; A Novelli; G Sibaï; F Mallet; S Cusack
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

3.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Electron cryotomography studies of maturing HIV-1 particles reveal the assembly pathway of the viral core.

Authors:  Cora L Woodward; Sarah N Cheng; Grant J Jensen
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

5.  The TY3 Gag3 spacer controls intracellular condensation and uncoating.

Authors:  Kristina Clemens; Liza Larsen; Min Zhang; Yurii Kuznetsov; Virginia Bilanchone; Arlo Randall; Adam Harned; Rhonda Dasilva; Kunio Nagashima; Alexander McPherson; Pierre Baldi; Suzanne Sandmeyer
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Flexibility in the P2 domain of the HIV-1 Gag polyprotein.

Authors:  John L Newman; Eric W Butcher; Dipti T Patel; Yelena Mikhaylenko; Michael F Summers
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

8.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.